Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence SLGSPSGEVSHPRKT
Primary information
sequence IDSeq_7324
Peptide sequenceSLGSPSGEVSHPRKT
CancerPDF_ID CancerPDF_ID1669, CancerPDF_ID3595, CancerPDF_ID12206,
PMID21136997,27026199,26992070
Protein NameAlpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein,Alpha-2-HS-glycoprotein
UniprotKB Entry NameFETUA_HUMAN,FETUA_HUMAN,FETUA_HUMAN
FluidSerum,Urine,Serum
M/Z1537.78487,NA,1537.7849
Charge1,NA,NA
Mass (in Da)NA,NA,1538.794163
fdrNA,1537.78,NA
Profiling TechniqueLC-MS,"CE-MS, Micro-TOF-MS",LC-MS
Peptide Identification techniqueLC-MS-MS/MS,MS-MS,LC-MS/MS
Quantification TechniqueLC-ESI-MS,NA,NA
Labelled/Label FreeLabel Free,Label Free,Label Free
FDRNA,NA,FDR 1 %
CancerPDF_ID CancerPDF_ID1669, CancerPDF_ID3595, CancerPDF_ID12206,
p-ValueNA,less than 0.05,NA
SoftwareMASCOT(v. 2.2.01),Proteome Discoverer 1.2,SEQUEST and Maxquant
Length15,15,15
Cancer TypeColorectal cancer,Bladder cancer,Melanoma
DatabaseSwissProt Database,Uniprot Human non-redundant Database,SwissProt Database
ModificationNA,NA,NA
Number of Patients30 patients and 30 healthy controls, 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls),8 cancer samples and 4 healthy samples
RegulationNA,Differentially expressed between recurrence of UBC vs recurrence control,"Present in 4 cancer samples out of 8 cancer samples. ,Present in 4 healthy samples out of 4 healthy samples."
ValidationLeave One out Cross validation,Independent Validation,na
SensitivityNA,For testing dataset 88%,NA
SpecificityNA,For testing dataset 51%,NA
AccuracyNA,NA,NA
Peptide AtlasNA
IEDB